Restricting Dexamethasone Use in Glioblastoma Treatment
Official title: Restrictive Use of Dexamethasone in Glioblastoma
Run by Insel Gruppe AG, University Hospital Bern · NCT04266977 · Data updated 2026-11-12
This study is testing if newly diagnosed glioblastoma patients can do well without the usual steroid treatment to see if it helps them avoid side effects and improve their outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Sankt Gallen, St.Gallen and 3 other locations) |
| Status | Recruiting |
| Started | May 8, 2020 |
| Main results expected | April 2027 |
| Study ends | April 2028 |
| Registry record updated | July 9, 2025 |
| Trial ID | NCT04266977 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 90 with newly diagnosed glioblastoma and specific neurological criteria.
✕Probably not a fit
Patients with infratentorial lesions, multifocal lesions, or those requiring steroids for other conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety of limiting the use of dexamethasone, a steroid commonly administered to glioblastoma patients, during their treatment. It aims to determine if selected patients can be treated effectively without the standard steroid regimen, which is associated with adverse side effects and poor prognostic outcomes. The study focuses on newly diagnosed glioblastoma patients who meet specific criteria, including age and neurological status, and excludes those with certain conditions or prior steroid use. By assessing the impact of reduced steroid use, the study seeks to improve patient outcomes and survival rates.
Why it matters
Potential benefit: If successful, this approach could lead to improved survival rates and reduced side effects for glioblastoma patients.
How similar studies have gone: While the use of dexamethasone in glioblastoma treatment is standard, this study's approach to restrict its use is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed supratentorial contrast enhancing lesion suspicious of glioblastoma without major mass effect, amenable to surgical resection * Age 18 - 90 years * Midline Shift ≤ 3mm * GCS ≥ 14 * NIHSS ≤ 3 * Provided written informed consent Exclusion Criteria: * Infratentorial lesions, brainstem lesions, multifocal lesions * Therapy with steroids for \>1 day before inclusion * Need for treatment with steroids due to any other disease * Contraindications to the administration of Dexamethasone * Pregnancy or breastfeeding
Where it's running
-
Department of Neurosurgery
Bern, Switzerland Recruiting -
Kantonsspital St. Gallen
Sankt Gallen, St.Gallen, Switzerland Not yet recruiting -
Universitätsspital Basel
Basel, Switzerland Not yet recruiting -
Universitätsspital Zürich
Zurich, Switzerland Not yet recruiting
Study contacts
- Principal investigator: Andreas Raabe, MD — Inselspital Bern, Department of Neurosurgery
- Study coordinator: Johannes Goldberg, MD
- Email: johannes.goldberg@insel.ch
- Phone: +41316322409
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Lixumistat window of opportunity in newly diagnosed glioblastoma
This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.
-
Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care
A large group of adults with diffuse gliomas in Réunion is being studied to understand how biology, culture, and health care pathways affect diagnosis and treatment.
-
Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care
This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.
-
Maintenance radiotherapy after standard glioblastoma treatment
This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.